C4 Therapeutics is a biotechnology company that develops small molecule drugs for the treatment of cancer and other diseases. The company's platform technology, called Targeted Protein Degradation (TPD), allows for the selective degradation of disease-causing proteins, which can lead to more effective and less toxic therapies. C4 Therapeutics is focused on developing drugs for difficult-to-treat cancers, such as KRAS-mutant tumors, as well as for neurodegenerative diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.